852391-20-9

Usage

Uses

Used in Pharmaceutical Industry:
Necrostatin-2 S enantioMer is used as a therapeutic agent for the treatment of diseases associated with necroptosis. Its application is based on its ability to inhibit the activity of RIPK1, a key mediator of necroptosis, which may offer potential for treating conditions where necroptosis plays a significant role.
Further research is necessary to fully understand the therapeutic potential of Necrostatin-2 S enantioMer and to explore its possible applications in human diseases.

Upstream product

• 75-44-5 phosgene 
• 74-88-4 methyl iodide 
• 77290-47-2 N-Acetyl-7-chlor-DL-tryptophan 
• 53924-05-3 7-chloro-1H-indole 
• 75102-74-8 7-chloro-D-tryptophan 
• 870481-89-3 2-amino-3-(7-chloro-1H-indol-3-yl)-N-methyl-propionamide 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 153-97-9 7-chloro-L-tryptophan 
• 852391-55-0 (S)-N-acetyl-7'-chlorotryptophan 

Relevant academic research and scientific papers

INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS

A compound having the following structure (I): or a pharmaceutically acceptable salt, prodrug, stereoisomer or tautomer thereof, is provided. Related compounds, methods for preparation of the same and uses of the compounds for treatment of various indications, including treatment of necrotic cell diseases and/or inflammation, are also provided.

Structure-activity relationship study of novel necroptosis inhibitors

Necroptosis is a regulated caspase-independent cell death mechanism that results in morphological features resembling necrosis. It can be induced in a FADD-deficient variant of human Jurkat T cells treated with TNF-α. 5-(1H-Indol-3-ylmethyl)-2-thiohydantoins and 5-(1H-indol-3-ylmethyl)hydantoins were found to be potent necroptosis inhibitors (called necrostatins). A SAR study revealed that several positions of the indole were intolerant of substitution, while small substituents at the 7-position resulted in increased inhibitory activity. The hydantoin ring was also quite sensitive to structural modifications. A representative member of this compound class demonstrated moderate pharmacokinetic characteristics and readily entered the central nervous system upon intravenous administration.

Inhibitors of cellular necrosis

The present invention relates to compounds and pharmaceutical preparations and their use in therapy for preventing or treating trauma, ischemia, stroke and degenerative diseases associated with cell death. Methods and compositions of the invention are particularly useful for treating neurological disorders associated with cellular necrosis.